Common Contracts
9 similar Underwriting Agreement contracts by AltheaDx, Inc., 89bio, Inc., Fulton Financial Corp, others
89BIO, INC. (a Delaware corporation) 11,455,882 Shares of Common Stock Pre- Funded Warrants to Purchase 3,250,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 14th, 2024 • 89bio, Inc. • Pharmaceutical preparations • New York
NOTICE REGARDING UNDERWRITING AGREEMENTUnderwriting Agreement • May 1st, 2024 • Fulton Financial Corp • National commercial banks • New York
The attached Underwriting Agreement is a contractual document that establishes and governs the legal relations among the parties with respect to the transactions described therein. The Underwriting Agreement is not intended to be a source for investors of factual, business, or operational information about the Company. The representations and warranties, covenants and agreements contained in the Underwriting Agreement were made only for purposes of the Underwriting Agreement, were solely for the benefit of the parties to the Underwriting Agreement, and may be subject to limitations agreed among those parties. Accordingly, investors and security holders should not rely on representations or warranties, covenants and agreements as characterizations of the actual state of facts or condition of the Company.
TARSUS PHARMACEUTICALS, INC. (a Delaware corporation) 2,812,500 Shares of Common Stock Pre-Funded Warrants to Purchase 312,500 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 1st, 2024 • Tarsus Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement with Goldman Sachs & Co. LLC (“Goldman”), BofA Securities, Inc. (“BofA”), Guggenheim Securities, LLC (“Guggenheim”) and each of the other underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Goldman, BofA and Guggenheim are acting as representatives (in such capacity, the “Representatives”), with respect to the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of (i) common stock, par value $0.0001 per share, of the Company (“Common Stock”) and (ii) pre-funded warrants, in the form set forth in Exhibit B hereto, to purchase shares of Common Stock (the “Pre-Funded Warrants”), each as set forth in Schedule A hereto, and (ii) the grant by the Company to the Underwriters, acting severally
Impel NeuroPharma, Inc. [•] Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • April 19th, 2021 • Impel Neuropharma Inc • Pharmaceutical preparations • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • December 4th, 2018 • Inspire Medical Systems, Inc. • Surgical & medical instruments & apparatus • New York
KARYOPHARM THERAPEUTICS INC. (a Delaware corporation) 3,902,439 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 26th, 2017 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • New York
AltheaDx, Inc. [—] Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • January 23rd, 2015 • AltheaDx, Inc. • Services-medical laboratories • New York
AltheaDx, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Citigroup Global Markets Inc. and Jefferies LLC (the “Representatives”) are acting as representatives, [—] shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [—] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singu
UNDERWRITING AGREEMENTUnderwriting Agreement • January 20th, 2015 • Tracon Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
TRACON Pharmaceuticals, Inc., a Delaware corporation (the “Company”) confirms its agreement with Wells Fargo Securities, LLC (“Wells Fargo”), Stifel, Nicolaus & Company, Incorporated (“Stifel”) and each of the other Underwriters named in Exhibit A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Wells Fargo and Stifel are acting as representatives (in such capacity, the “Representatives”), with respect to the issue and sale by the Company of a total of [·] shares (the “Initial Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Initial Securities set forth in said Exhibit A hereto, and with respect to the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all
AltheaDx, Inc. [—] Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • December 23rd, 2014 • AltheaDx, Inc. • Services-medical laboratories • New York
AltheaDx, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom Citigroup Global Markets Inc. and Jefferies LLC (the “Representatives”) are acting as representatives, [—] shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [—] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singu
